Pomerantz LLP is investigating HCA Healthcare following the company's sharp reduction in its 2026 profit guidance due to an unfavorable payer mix that impacted revenue by about $400 million in Q2. This announcement caused HCA's stock to drop nearly 7% on July 14, 2026. The investigation focuses on whether HCA and its executives engaged in securities fraud or other unlawful practices. Investors affected by this may join a class action lawsuit being pursued by the law firm.
HCA Healthcare's stock dropped nearly 7% on July 14, 2026, following a sharp reduction in its 2026 profit guidance. For readers following health-sector US stocks, here is Pluang's market snapshot as of Oct 21, 2026 03:11 WIB: out of 150 priced stocks, 124 rose and 26 fell. Notable movers include SLS at USD 11.94 with a 13.82% increase and ISRG at USD 390.00 with a 9.97% decrease, while RLAY rose 8.54% to USD 18.55.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
